中药材2024，Vol.47Issue(5)：1253-1259,7.DOI:10.13863/j.issn1001-4454.2024.05.031
丹参酮ⅡA通过干预PSMD14表达影响结直肠癌细胞放疗敏感性的机制研究
Study on the Mechanism of the Effect of Tanshinone ⅡA on the Radiotherapy Sensitivity of Colorectal Cancer Cells by Intervening PSMD14 Expression
摘要
Abstract
Objective:To investigate the effect of tanshinone ⅡA on radiotherapy sensitivity of colorectal cancer cells and its regu-latory mechanism on PSMD14 expression.Methods:Colon cancer HCT116 cells were divided into blank control group,radiotherapy(4Gy irradiation)group,radiotherapy with tanshinone ⅡA low(0.01 mg/L),high(0.02 mg/L)concentration groups,radiotherapy with tan-shinone ⅡA high concentration and PSMD14 overexpression(pc-PSMD14)group.The proliferative activity of the cells was detected by MTT assay.The apoptosis rate was detected by Hoechst333258 staining assay.The cell cycle was measured by flow cytometry.DNA damage was detected by comet assay.The expressions of CDK3 and CyclinD1 were detected by immunohistochemistry.The expressions of DNA-PK and γ-H2AX proteins were detected by immunofluorescence.The mRNA expressions of PSMD14,CyclinD1,CDK3,DNA-PK,γ-H2AX and Bcl-2 were detected by PCR.The PSMD14,Bcl-2,Bax protein expressions were detected by Western Blot.Results:Radiation irradiation could significantly reduce the proliferation of colon cancer HCT166 cells,block its cell cycle,induce its DNA dam-age,increase its apoptosis rate,while tanshinone ⅡA could significantly enhance the sensitivity of cells to radiation,overexpression of PSMD14 could partially reverse the sensitization effect of tanshinone ⅡA.Conclusion:Tanshinone ⅡA can significantly enhance the ra-diotherapy sensitivity of cells,and the mechanism may be related to the inhibition of PSMD14 expression in cells.关键词
丹参酮ⅡA/结直肠癌/放疗敏感性/26S蛋白酶体非ATP酶调节亚基14Key words
Tanshinone ⅡA/Colon cancer/Radiosensitivity/26S Proteasome non-ATPase regulatory subunit 14分类
医药卫生引用本文复制引用
成植温,王滨,宫凯凯,马静,董宁霞..丹参酮ⅡA通过干预PSMD14表达影响结直肠癌细胞放疗敏感性的机制研究[J].中药材,2024,47(5):1253-1259,7.基金项目
国家自然科学基金青年科学基金项目(81903537) （81903537）
山东中医药学会临床药学科研专项基金项目(SDACM202209) （SDACM202209）
